Lugano (ots) - Helsinn Group announces that on September 18th it has signed a license agreement with CJ CheilJedang, Korea for Helsinn's new product for potential use in the prevention of chemotherapy-induced nausea and vomiting (CINV). The agreement covers the exclusive license and distribution rights for a ...
Lugano, Switzerland / Raleigh, N.C., USA (ots) - Gelclair® Strengthens DARA's Growing Portfolio of In-licensed Oncology and Oncology Supportive Care Products The Helsinn Group of Switzerland announced today that it has entered into an exclusive agreement with DARA BioSciences, Inc. (Nasdaq: DARA) for U.S. ...
Lugano, Switzerland (ots) - Starting July 1st the Swiss Group has become Gold sponsor of the Sharing Progress in Cancer Care (SPCC) Programme Through its support to the Sharing Progress in Cancer Care (SPCC) Programme, Helsinn Group starts to actively collaborate with the European School of Oncology (ESO) in promoting education in oncology, with special attention to cancer supportive care. SPPC is a collaborative ...
Munich (ots) - Jan Van Ruymbeke, 53, will become the new Chief Executive Officer of Daiichi Sankyo Europe this autumn. The native of Belgium will replace Reinhard Bauer, who is retiring after 10 years in this position. Van Ruymbeke will assume responsibility for the pharmaceutical company in October. Until the end ...
Oss, The Netherlands (ots) - Movianto Nederland, the logistics and transportation company specialised in pharmaceuticals and healthcare, is set to begin operations in the new state-of-the- art warehouse especially built to meet the clients' needs. The strategically located warehouse also offers the largest facility for the storage of deep frozen pharmaceutical products ...
Parsippany, NJ (ots) - - Creates 3rd largest global generics company - - ~$8.0 billion anticipated pro forma combined revenue in 2012 - - Significantly increases scale of Watson's ex-U.S. generic business- - Accelerates revenue and earnings growth - - Immediately accretive to non-GAAP earnings, before synergies - - Greater than $300 million annual synergies anticipated within 3 years - - Strong combined cash flow allows ...
Chicago, Illinois (ots) - --Results Support Differentiating Drug-like Features for Targeted Anti-cancer Drug-- Pieris AG announced today the presentation of a range of in vitro and in vivo preclinical data for the company's proprietary c-Met antagonist program, PRS-110, at the American Association for Cancer ...
Bern, Switzerland (ots) - - - Quality of Life (QoL) is strongly diminished in RVVC patients - Current available treatment fails in two thirds of patients - High medical need demands novel effective treatment options Pevion Biotech AG today announced results from a large, international survey on the Quality of Life ...
Freising, Germany (ots) - Pieris AG announced today the receipt of a EUR 1 million grant to support the development of the company's proprietary PRS-110 compound targeting c-Met, a cellular receptor that plays a key role in cancer cell growth and metastasis. The goal of the funded research will be to delineate a ...
Warsaw, Poland (ots) - Actavis and Bioton (WSE:BIO) announced today that they have formed a joint venture company for the development and registration of insulins, including analogue insulins. Within the framework of the joint-venture, Bioton will be responsible for the development and manufacture of insulin ...
San Diego, CA, USA (ots) - Breadth of Pharmacokinetic Data Points to Tunable Half-life for Platform Pieris AG presented novel preclinical in vitro and in vivo data for its PRS-080 Anticalin hepcidin antagonist in an oral presentation at the American Society of Hematology Annual Meeting, the company announced today. ...
Zurich, Switzerland (ots) - NHS National Innovation Centre supports the cost effectiveness of Sequana Medical's ALFApump System Sequana Medical announced today the findings of an independent economic assessment of the ALFApump System commissioned by the National Innovation Centre, the NHS organization which supports ...
Lausanne, Switzerland (ots) - A new study shows self-centered CEOs who "crave acclaim and applause" are more likely to keep their companies at the forefront of technological innovation. Additionally, the desire for attention from self-absorbed CEOs fuels the willingness to make daring decisions that less confident counterparts might shy away from, especially during a period of radical change. Conducted by professors at ...
San Francisco, California (ots) - --Results Establish Safety, Tolerability, Lack of Immunogenicity and PK/PD Profile for First Anticalin in a Clinical Setting-- Pieris AG presented the results of the Company?s first clinical evaluation of its most advanced Anticalin®, PRS-050, an anti-VEGF targeted protein ...
Freising (ots) - In concert with the award of the EU FP7 Grant to the Pieris-led EUROCALIN Consortium that will enable initial clinical development of Pieris' proprietary hepcidin antagonist program, the company announced today the positive strategic impact of the grant funding on its proprietary Anticalin pipeline. ...
Freising, Germany (ots) - - Consortium Will Receive Six Million Euro from Seventh Framework Programme The EUROCALIN Consortium, comprising 10 companies and universities from across Europe, has initiated a collaboration focused on attaining and completing initial clinical development of a novel Anticalin® ...
Zejtun, Malta (ots) - "We know Libya is faced with shortages of essential supplies. That's why Actavis donates EUR 2M worth of medicines to Libya now. The goods will leave Malta on Sunday and arrive in Tripoli during next week", said Actavis CEO Claudio Albrecht. "Actavis is one of the world's largest generic pharmaceutical players and takes its social responsibility very seriously." Mr. Albrecht emphasized the role of ...
Ittigen/Bern, Switzerland (ots) - Pevion Biotech AG today announced latest results from the ongoing clinical study of its therapeutic Candida vaccine PEV7, showing high levels of specific antibodies and a 100% mucosal immune response rate. The announcement further included the results of the largest, international ...
Roche Professional Diagnostics
Rotkreuz, Switzerland/Asnieres, France (ots) - Roche Professional Diagnostics and Diagnostica Stago announced today that the companies have decided to pursue separate paths in the business of Laboratory Coagulation in the territories where Roche distributed the Stago product range. The exclusive sales of Stago products by Roche will continue throughout the entire year of 2011. With the exception of Japan where Roche ...
Lugano, Switzerland and Greifswald, Germany (ots) - Helsinn Healthcare SA, Switzerland and Riemser Arzneimittel AG, German licensee of Helsinn's second generation 5-HT3 receptor antagonist palonosetron, announce today the signing of a licensing agreement granting Riemser the commercialization rights for a ...
Lugano, Switerland (ots) - The Company has entered the Phase III clinical program for both its investigational medications anamorelin, in non-small cell lung cancer-associated anorexia/cachexia, and netupitant + palonosetron oral fixed-dose combination in chemotherapy-induced nausea and vomiting (CINV) Helsinn, the Swiss pharmaceutical Group, global leader in the segment of the prevention of chemotherapy-induced nausea ...
Lugano, Switzerland and Woodcliff Lake, NJ, USA (ots) - Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and ...
Ittigen/Bern, Switzerland (ots) - Pevion Biotech AG today announced that the company has granted to CSL Limited a right of first refusal for the commercialization of its therapeutic Candida vaccine in Australia and New Zealand. At the same time, both companies signed a long-term supply agreement under which CSL shall supply to Pevion components for its virosomal vaccines. CSL, Australia's leading biopharmaceutical ...
Zurich, Switzerland (ots) - New technology expands treatment options for patient with refractory ascites due to liver cirrhosis. Dr. Farzana Malik joins as Vice President of Market Access and Reimbursement. Sequana Medical announced today that it has received CE Mark approval for the commercial sale of its ALFApump System. Over the coming months, the company will ...
Amsterdam, The Netherlands (ots) - New data presented at the 14th World Conference on Lung Cancer in Amsterdam, The Netherlands, show the efficacy of the 2nd generation 5-HT3 receptor antagonist alone and in combination with aprepitant New data on the 2nd generation 5-HT3 receptor antagonist palonosetron, in the ...
European Renal Association - European Dialysis and Transplant Association (ERA-EDTA)
Prague (ots) - The SHARP-study has shown that lowering LDL cholesterol with ezetimibe/simvastatin leads to a significant reduction in major atherosclerotic events among CKD-patients. Whether it also has a favourable effect on renal disease progression was another of the issues addressed by the SHARP study [abstract ...
European Renal Association - European Dialysis and Transplant Association (ERA-EDTA)
Prague, Czech Republic (ots) - The randomised, double-blind, placebo-controlled multi-centre study (abstract no. 2511) investigated the efficacy and safety of the monoclonal antibody rituximab (RTX) in 197 ANCA-associated vasculitis (AAV) patients. This study showed that in patients with severe AAV a single course ...
Freising (ots) - Pieris AG announced today preclinical in vitro and in vivo data for its PRS-080 Anticalin antagonist program targeting hepcidin, a small peptide which plays a pivotal role in the regulation of iron levels in the blood. PRS-080 showcases Anticalins' ability to encapsulate small targets like hepcidin ...
Lugano, Switzerland/Sandpoint, ID (ots) - Helsinn Group makes an equity investment for a minority interest in Thorne Research, Inc. and plans to jointly commercialize nutritional supplement products with initial focus on meeting the needs of people living with cancer Helsinn Group a rapidly growing pharmaceutical ...
WMDO SA - World Medical Device Organization
Helsinki (ots) - (Jan. 11, 2011) The National Association Representing the Entire Finnish Health Technology Sector Will Now Offer its Members Convenient Online Training Built Specifically for Medical Device Professionals The Finnish Health Technology Association (FiHTA) and the World Medical Device Organization ...